0001193125-12-294109.txt : 20120803 0001193125-12-294109.hdr.sgml : 20120803 20120705070022 ACCESSION NUMBER: 0001193125-12-294109 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120705 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RXi Pharmaceuticals Corp CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 60 PRESCOTT STREET CITY: WORCESTER STATE: MA ZIP: 01605 BUSINESS PHONE: 800-794-6027 MAIL ADDRESS: STREET 1: 60 PRESCOTT STREET CITY: WORCESTER STATE: MA ZIP: 01605 CORRESP 1 filename1.htm Correspondence

July 5, 2012

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-4628

 

Re: RXi Pharmaceuticals Corporation (the “Company”)

Registration Statement on Form S-1

Filed May 18, 2012

File No. 333-181534

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:00 p.m. (Eastern) on Friday, July 6, 2012, or as soon thereafter as practicable.

In making this acceleration request, the Company acknowledges that:

 

  •  

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 

  •  

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

  •  

the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

Sincerely,
By: RXi Pharmaceuticals Corporation

/s/ Geert Cauwenbergh

Geert Cauwenbergh, Dr. Med. Sc.
President and Chief Executive Officer

 

cc: Ryan Murr, Esq. (Ropes & Gray LLP)